BC Extra | May 8, 2019
Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

Viva will begin trading Thursday after raising HK$1.5 billion (US$193.9 million) early Wednesday in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech Holdings (HKSE:1873) sold 345 million...
BC Week In Review | Feb 8, 2019
Financial News

Frazier-backed Recida launches with $8.5M series A

Recida Therapeutics Inc. (Menlo Park, Calif.) raised $8.5 million in a series A round led by Frazier Healthcare Partners as it completed a pair of deals involving its lead compound RC-01. The new company gained...
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
BC Week In Review | Jan 9, 2019
Financial News

MicuRx refiles for Hong Kong listing

MicuRx Pharmaceuticals Inc. (Foster City, Calif.) refiled on Dec. 31 to list on the Hong Kong stock exchange, with Jefferies as the sole underwriter. The anti-infectives company had originally filed in June, but its application...
BC Extra | Aug 8, 2018
Financial News

BeiGene dips slightly in Hong Kong debut

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) slipped HK$1 to HK$107 in its first day of trading on the Hong Kong exchange Wednesday. Last week, the company raised HK$7.1 billion ($902.7 million) by pricing its Hong Kong listing...
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
BC Extra | Aug 3, 2018
Financial News

Ascletis ends first trading week on downturn

Ascletis Pharma Inc. (HKSE:1672) sank HK$1.84 (16%) to HK$10.02 on Friday, ending its first week of trading down 28% from its IPO price of HK$14. This week, Ascletis became the first biotech to go public...
BC Week In Review | Aug 3, 2018
Financial News

BeiGene prices Hong Kong listing

BeiGene Ltd. (NASDAQ:BGNE) raised on Aug. 2 HK$7.1 billion (US$902.7 million) through the sale of 65.6 million shares at HK$108 in its listing on the Hong Kong stock exchange. BeiGene, which priced the offering toward...
BC Extra | Aug 2, 2018
Financial News

BeiGene prices Hong Kong listing

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) raised HK$7.1 billion (US$902.7 million) early Thursday through the sale of 65.6 million shares at HK$108 in its listing on the Hong Kong stock exchange. The cancer company, which priced the...
BC Extra | Aug 1, 2018
Financial News

Ascletis trades flat in Hong Kong debut

Ascletis Pharma Inc. (HKSE:1672) shares ended the day unchanged at HK$14 in the company's first day of trading Wednesday. The antiviral company raised HK$3.1 billion ($400 million) in its IPO through the sale of 224.1...
Items per page:
1 - 10 of 37